Martin D. Meglasson
Plus aucun poste en cours
Profil
Dr. Martin D.
Meglasson is Chief Scientific Officer & Vice President at Bellerophon Therapeutics, Inc.
Dr. Meglasson was previously employed as Chief Scientific Officer by Ikaria, Inc., Vice President-Discovery Research by Ligand Pharmaceuticals, Inc., a Director-Preclinical Pharmacology by Pharmacia, Inc., and a Director-Endocrine & Metabolic Research by Pharmacia & Upjohn, Inc.
He received his doctorate degree from the University of Houston.
Anciens postes connus de Martin D. Meglasson
| Sociétés | Poste | Fin |
|---|---|---|
| IKARIA, INC. | Directeur Technique/Scientifique/R&D | 01/01/2014 |
| LIGAND PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | 23/07/2010 |
| Pharmacia, Inc. | Directeur Technique/Scientifique/R&D | 01/01/2003 |
| Pharmacia & Upjohn, Inc. | Corporate Officer/Principal | 01/01/1998 |
| BELLEROPHON THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | - |
Formation de Martin D. Meglasson
| University of Houston | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| LIGAND PHARMACEUTICALS INCORPORATED | Health Technology |
| BELLEROPHON THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
| Pharmacia & Upjohn, Inc. | Health Technology |
| Pharmacia, Inc. | |
Ikaria, Inc.
 Ikaria, Inc. BiotechnologyHealth Technology Ikaria, Inc. operates as a biotherapeutics company focused on developing and commercializing innovative therapeutics and interventions designed to meet the medical needs of critically ill patients. It offers INOMAX for inhalation, which is used to treat newborns suffering from hypoxic respiratory failure, and is making a major impact on the critical care environment. The company was founded on August 18, 2006 and is headquartered in Clinton, NJ. | Health Technology |
